Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Thymoma and Thymic Carcinoma
For the neoadjuvant treatment for thymoma, when do you favor CAP with prednisone over CAP?
CAP with prednisone:
Kim et al., PMID 15140551
Answer from: Medical Oncologist at Academic Institution
Yes, due to the MD Anderson trial that used CAP+prednisone. However, there are no randomized data. I use carbo-taxol for thymic carcinoma.
Sign In
or
Register
to read more
31233
Related Questions
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
Would you continue tarlatamab in CNS-only progression of small cell cancer if there is no systemic disease?
Would you add immunotherapy to chemotherapy for a patient with metastatic NSCLC, an atypical EGFR mutation, and PD-L1 ≥50% who has progressed on osimertinib?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
How do you approach duration of immunotherapy in patients with metastatic NSCLC?
For a patient with NSCLC harboring an EGFR or ALK mutation that transforms into SCLC, would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?
How would you treat a patient with metastatic NSCLC, adenocarcinoma subtype with BRAF V600K mutation, PD-L1 >50% with progression on 1st line chemo-immunotherapy?
What is your preferred treatment option after tarlatamab for patients with ES-SCLC?
When should a biopsy be obtained to rule out small cell transformation in a patient with stage IV NSCLC and an EGFR mutation?